Table 3.

Adjusted hazard ratios for locoregional recurrence among all patients.

Variable	Hazard Ratio (95% CI)	P-value
Hormone Receptor Subgroup
ER/PR+* / HER2*-negative	1.00	-
ER/PR+ / HER2+ / No Trastuzumab	2.11 (1.25 – 3.58)	0.005
ER/PR+ / HER2+ / Yes Trastuzumab	1.24 (0.56 – 2.73)	0.591
Triple-negative	4.73 (3.42 – 6.54)	<0.001
ER/PR-negative / HER2+ / No Trastuzumab	2.32 (1.32 – 4.07)	0.004
ER/PR-negative / HER2+ / Yes Trastuzumab	2.01 (1.04 – 3.87)	0.037
Age at Diagnosis	0.99 (0.97 – 1.00)	0.025
Stage Group
I	1.00	-
II	1.68 (1.06 – 2.66)	0.028
III	4.28 (2.52 – 7.27)	<0.001
LVSI†
No	1.00	-
Yes	3.06 (2.30 – 4.08)	<0.001
Chemotherapy
Neoadjuvant	1.00	-
Adjuvant	0.64 (0.46 – 0.89)	0.007
Both	0.68 (0.43 – 1.06)	0.091
Surgery/Radiation
BCT‡ + RT‡	1.00	-
Mastectomy + RT	0.96 (0.67 – 1.38)	0.836
Mastectomy no RT	2.01 (1.39 – 2.91)	<0.001

^*ER/PR+ = Estrogen receptor and/or progesterone receptor positive; HER2 = Human epidermal growth factor receptor 2

^†LVSI = Lymphovascular space invasion

^‡BCT = Breast conservation therapy; RT = Radiation therapy